Feature | July 29, 2014

MitraClip Procedure Repairs One Heart Structurally, Another Emotionally

MitraClip Abbott Vascular Heart Valve Repair University of Alabama at Birmingham

July 29, 2014 — Mary York knew the walk from the living room to the bedroom should not have been difficult for her husband, Bill, despite his age, but the 83-year-old could not walk anywhere in his house without stopping to rest for minutes at a time.

“He just couldn’t breathe, couldn’t catch his breath, and that was with him just barely moving,” Mary York said. “When Bill finally told me one night that he didn’t want to live anymore, it just broke my heart.”

The Yorks had driven from their home in Cullman, Ala., to Birmingham, Ala., and visited several cardiologists, trying to find a solution to Bill York’s condition, mitral regurgitation. They tried different medications, and even open-heart surgery was recommended for him — a prospect Mary York did not think her husband could survive.

A family friend encouraged them to visit cardiologists at the University of Alabama at Birmingham to get another opinion, and it was one she believes saved his life.

Bill York recently became among the first patients in Alabama and the United States to receive a MitraClip device in a breakthrough, new minimally invasive treatment option used to aid patients suffering from mitral regurgitation. Oluseun Alli, M.D., director of the structural heart program in the UAB School of Medicine Section of Interventional Cardiology, and Massoud Leesar, M.D., professor of medicine and section chief of interventional cardiology, performed the procedure on June 24. Two weeks later, Bill York walked six minutes nonstop on his follow-up visit.

“MitraClip therapy is a groundbreaking treatment for mitral regurgitation, which is the most common type of heart valve insufficiency,” Alli said. “This device is currently the only minimally invasive treatment we have for these high-risk patients, and it is the only device that has been effective in treating severe mitral regurgitation apart from open surgical repair or replacement. Open surgical repair or replacement is still the standard of care for patients who can undergo open-heart surgery, and the MitraClip is approved for use in high-risk surgical patients, like Mr. York.”

Mitral regurgitation, which is progressive and life-threatening, occurs when the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart during the cardiac cycle. The heart then has to compensate to provide adequate blood flow, which causes the left ventricle to increase in size. That causes the heart to work harder, and can raise the risk of irregular heartbeat, stroke and heart failure, which can be deadly.

The MitraClip enables interventional cardiologists like Alli to deliver the clip through the femoral vein in the groin to the affected area along the mitral valve within the heart. Once there, the cardiologist delivers the clip, which attaches the mitral valve together to create a double-barreled orifice.

“We pull the edges of the two leaflets of the valve together using the MitraClip,” Alli said. “The valve leaflets become fused together, with creation of a double-barreled valve orifice with two holes side-by-side that allows the blood to go forward but prevents it from coming backward.”

MitraClip, manufactured by Abbott, is a nonsurgical treatment and necessary for patients like York. The medications he was prescribed were designed to control and relieve the symptoms of mitral regurgitation, but there are no medications available to correct it. The medications, however, did not relieve his symptoms, and Bill York had fluid buildup in his legs and lungs, making his condition dire.

Open-heart surgery can be performed to replace the damaged mitral valve with a mechanical or bioprosthetic valve; but Louis Brunsting, M.D., associate professor of surgery and chief of the section of minimally invasive cardiac surgery, did not believe that was a feasible option for York, whose condition left him extremely frail.

“Because we have a comprehensive valve program, where every patient is seen by a surgeon and interventional cardiologist, we were able to find the best course of treatment for Mr. York,” Alli said. “There are a lot of Mr. Yorks out there who need help, who suffer from severe mitral regurgitation and can’t find relief from medication and are not good candidates for surgery. We’re excited to be the only center in Alabama and one of only a handful of centers in the United States to offer this device.”

Mitral regurgitation affects nearly one in 10 people ages 75 and older and approximately 4 million people in the United States alone.

The U.S. Food and Drug Administration (FDA) approved the MitraClip for the treatment of mitral regurgitation for commercial use in the United States in October 2013. Patients undergoing the procedure typically experience short recovery times and an average hospital stay of only three days. York went back home to Cullman a few days after his procedure.

“I feel great for an old man,” York said. “My breathing is so much better now. It’s exciting to feel good again.”

It is a good feeling for his wife, too.  

“We’ve been married for 65 years; he’s my first love, and he’s my last love,” Mary York said. “He’s not only my husband, he’s my best friend. I’m so thankful and appreciative for Dr. Alli and everyone at UAB who helped us find the answers to our problem. It means more than I can explain.”

For more information: www.uab.edu/news

Related Content

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Medtronic Shares Two-Year Harmony Transcatheter Pulmonary Valve Results at SCAI 2018. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
Medtronic plc announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Colibri Heart Valve Continues Enrollment in TAVI Early Feasibility Study
News | Heart Valve Technology | May 07, 2018
Colibri Heart Valve LLC announced the Colibri transcatheter aortic valve implantation (TAVI) System has been used on an...
An 3D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

A 3-D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

,

Edwards Lifesciences puchased Valtech to acquire the CardioBand transcatheter annuloplasty system technology. It received market clearance in Europe in April 2018.

Feature | Heart Valve Technology | May 04, 2018 | Dave Fornell, Editor
May 4, 2018 — Transcatheter val...
Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy - Cardioband Tricuspid Valve Reconstruction System
News | Heart Valve Technology | May 01, 2018
Edwards Lifesciences Corp.announced that it received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction...
Boston Scientific Prevails in European Patent Dispute With Edwards Lifesciences
News | Heart Valve Technology | April 26, 2018
The European Patent Office (EPO) has revoked Edward Lifesciences’ Corp.’s European patent EP 2,399,550 (‘550), ruling...
A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient.

A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient. 

 

Feature | Heart Valve Technology | April 20, 2018 | Dave Fornell
While there is fear by many about the trend of hospitals consolidating into larger healthcare systems, one advantage
A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

, , , ,

An illustration showing the transcaval access cross over point between the venous and arterial systems. 

Feature | Heart Valve Technology | April 19, 2018 | Dave Fornell
Patient selection for who is best suited for a ...
Overlay Init